Department of Neurology, Akasaka Sanno Medical Center, Clinical Research Center for Medicine, International University of Health and Welfare, Tokyo, Japan.
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Cerebrovasc Dis Extra. 2024;14(1):86-94. doi: 10.1159/000540254. Epub 2024 Jul 23.
Recent advances are in the genetics, diagnosis, pathophysiology, and management of moyamoya disease (MMD), and moyamoya syndrome (MMS), a term used to describe moyamoya-like vasculopathy associated with various systemic diseases or conditions.
Ring finger protein (RNF213) has been reported to be a susceptibility gene not only for MMD but also for atherosclerotic intracranial arterial stenosis and ischemic stroke attributable to large artery atherosclerosis. The latest guidelines by the Research Committee on MMD of the Japanese Ministry of Health, Labor, and Welfare, removed limitations of the previous definition that required bilateral involvement of the intracranial carotid artery to make the diagnosis, given the increasing evidence of progression to bilateral involvement in unilateral MMD. 3-dimensional constructive interference in steady-state MRI is useful for the differential diagnosis of MMD from atherosclerosis. Recent advances in the pathophysiology of MMD suggest that genetic and environmental factors play important roles in vascular angiogenesis and remodeling via complex mechanisms. The latest Japanese Guidelines and American Scientific Statement described that antiplatelet therapy can be considered reasonable. Endovascular interventional stent placement fails to prevent ischemic events and does not halt MMD progression. In the Japan Adult Moyamoya trial, a randomized controlled trial for bilateral extracranial-intracranial direct bypass versus conservative therapy in patients with MMD, who had intracranial hemorrhage, recurrent bleeding, completed stroke, or crescendo transient ischemic attack was significantly fewer with direct bypass than with conservative care.
This review presents updated information on genetics, diagnosis, pathophysiology, and treatment of adult MMD and MMS. Despite recent advances, many mysteries still exist in the etiologies of moyamoya vasculopathy. The diagnostic criteria and treatment guidelines have been updated but not yet been globally established. Ongoing and future studies investigating underlying pathophysiological mechanisms of MMD and MMS may clarify potentially effective medical, surgical, or endovascular treatments.
近来,在遗传学、诊断学、病理生理学和 moyamoya 病(MMD)及 moyamoya 综合征(MMS)的治疗方面都取得了进展。MMS 是一个术语,用于描述与各种系统性疾病或病症相关的 moyamoya 样血管病变。
环状指蛋白(RNF213)不仅是 MMD 的易感基因,也是粥样硬化性颅内动脉狭窄和大动脉粥样硬化性缺血性卒中的易感基因。鉴于单侧 MMD 向双侧进展的证据越来越多,日本厚生劳动省 MMD 研究委员会的最新指南对先前需要双侧颅内颈内动脉受累才能做出诊断的定义进行了修改。稳态三维干扰磁共振成像对于 MMD 与动脉粥样硬化的鉴别诊断很有用。MMD 病理生理学的最新进展表明,遗传和环境因素通过复杂的机制在血管生成和重塑中发挥重要作用。最新的日本指南和美国科学声明指出,抗血小板治疗是合理的。血管内介入支架置入术不能预防缺血事件,也不能阻止 MMD 的进展。在日本成人 moyamoya 试验中,一项针对 MMD 伴颅内出血、复发性出血、完成性卒中或渐强短暂性脑缺血发作患者的双侧颅内外直接旁路与保守治疗的随机对照试验中,直接旁路治疗的患者发生缺血性事件和进展性卒中和的人数明显少于保守治疗。
本文综述了成人 MMD 和 MMS 的遗传学、诊断学、病理生理学和治疗的最新信息。尽管取得了一些进展,但 moyamoya 血管病变的病因仍有许多未解之谜。诊断标准和治疗指南已经更新,但尚未在全球范围内确立。正在进行和未来的研究调查 MMD 和 MMS 的潜在病理生理学机制,可能会阐明潜在有效的药物、手术或血管内治疗方法。